Hypothesis

Aligning probiotic administration with the host's circadian rhythm enhances microbiota‑mediated modulation of the tryptophan‑kynurenine pathway, thereby reducing neuroinflammation and depressive symptoms more effectively than constant dosing.

Mechanistic Rationale

Circadian clocks in intestinal epithelial cells regulate the expression of nutrient transporters and enzymes that shape microbial metabolism. For example, the clock‑controlled gene Nr1d1 drives rhythmic expression of arylamine N‑acetyltransferase, influencing the availability of tryptophan for bacterial conversion into indole derivatives. These microbial metabolites act as ligands for the host aryl hydrocarbon receptor (AhR) in dendritic cells, biasing them toward a tolerogenic phenotype and lowering proinflammatory cytokine production. When probiotic strains such as Lactobacillus rhamnosus JB-1 are given at the peak of host circadian sensitivity (e.g., early active phase), their GABA‑producing capacity and tryptophan‑metabolizing activity are amplified, leading to greater downstream increases in brain BDNF and reductions in microglial activation. Conversely, mistimed administration coincides with low transporter expression, resulting in weaker microbial signaling and diminished therapeutic impact.

Testable Predictions

1. Patients receiving timed probiotic dosing will show a larger increase in fecal indole‑3‑propionic acid and a greater decrease in plasma kynurenine/tryptophan ratio compared with those receiving the same probiotic at random times.
2. Timed dosing will produce a bigger rise in heart‑rate variability (a proxy for vagal tone) and a larger reduction in depressive symptom scores (MADRS) after 8 weeks.
3. Microbiome‑derived AhR ligand levels will correlate positively with changes in peripheral cytokine levels (IL‑6, TNF‑α) and inversely with microglial activation markers measured via PET translocator protein imaging in a subset of participants.

Experimental Design

A double‑blind, randomized, crossover trial with 60 participants diagnosed with moderate major depressive disorder. Each participant receives two 4‑week interventions separated by a 2‑week washout: (A) L. rhamnosus JB-1 (1 x 10^9 CFU) administered at 08:00 h (aligned with the human morning activity peak) and (B) the same dose given at 20:00 h (misaligned). Primary outcomes: change in MADRS score, fecal indole‑3‑propionic acid, plasma kynurenine/tryptophan ratio, and HRV. Secondary outcomes: cytokine panel, and optional PET imaging for microglial activation in 15 participants. Statistical analysis will use mixed‑effects models to test interaction between timing and treatment. A significant timing × treatment interaction supporting prediction 1‑3 would falsify the null hypothesis that circadian timing does not influence probiotic efficacy.